An observational study in Preoperative Care, Surgery--Complications and Myocardial Infarction, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 16 sites in 4 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Myocardial Infarction with a site in Canada — 18 open to participants now, 30 under way, 9 of them phase 3. Myocardial Infarction · Canada.
Among the 171 studies in Myocardial Infarction with a site in Canada, this one is the 7th largest by planned enrollment of the 36 observational ones that give a count, is one of 8 that started in 2021, is one of 36 observational ones, reaches primary completion later than 13 of the 29 other live ones, and was the 149th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →18 of the 171 studies in Myocardial Infarction with a site in Canada are open now. Recruiting first, the newest first:
Montreal Heart Institute · Sites in Canada
Ages 18+
Amgen · Sites in Canada, United States, Australia and 1 more country
Ages 50–105
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
CSL Behring · Sites in Canada, United States, Argentina and 32 more countries
Ages 18+
Laval University · Sites in Canada
Ages 18–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 27 · Phase 3 51 · Phase 4 22
First in 1999; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15,000 is above the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Median enrollment 500 across the 135 interventional studies, 1,060 across the 36 observational. Of the 119 that completed or were terminated, 38 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 171 have an industry lead sponsor. The 10 most frequent:
Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Centre hospitalier de l'Université de Montréal (CHUM) has 3 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
10 of the studies in Myocardial Infarction with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT06174753Phase 3Ottawa Heart Institute Research CorporationDapagliflozin in STEMI | 2027-06 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT07171580St. Boniface HospitalTailoring Post Discharge - Remote Education and Access for Cardiac Health | 2026-11-30 |
| NCT04973397Centre hospitalier de l'Université de Montréal (CHUM)Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 171 studies in Myocardial Infarction with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proportion of noncardiac surgeries performed as same-day surgery is increasing worldwide, with more complex surgeries being performed on higher risk patients in the outpatient setting. Little is known on the risk factors, incidence and prognosis of patients undergoing same-day noncardiac surgery. The main objective of this study is to inform on the incidence and risk factors of cardiovascular and other adverse events after same-day surgery and to develop risk prediction tools to better inform on the risk and selection of patients undergoing same-day surgery.
The VALIANCE Study is a 15,000 patient, multicentre, prospective observational cohort of adults undergoing elective same-day noncardiac surgery and who will be followed for 90 days after surgery. The primary objective of the study is to determine the incidence of major cardiovascular complications after same-day surgery. Patients will also be followed for the occurence of other adverse postoperative complications and determine their change in quality of life at 90 days after surgery. VALIANCE will inform on the risk factors for postoperative complications and allow to develop risk prediction tools to guide patient selection and risk stratification of patients undergoing same-day surgery. The study will also look at validating the use of the Duke Activity Status Index questionnaire, Clinical Frailty Scale, and the Revised Cardiac Risk Index. Postoperative pain will be evaluated using the Brief pain inventory score and quality of life using the EQ-5D-5L questionnaire.
All eligible adults undergoing elective same-day noncardiac surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Unplanned healthcare utilization
the number of patients who have at least one of the following: unplanned admission after surgery, unplanned outpatient visit, emergency room visit and rehospitalization after same-day surgery
Time frame: 90 days
unplanned admission
the number of patients who have to be admitted to the hospital after undergoing a surgery planned as same-day
Time frame: 90 days
unplanned outpatient visit
the number of patient who had a medical visit in an outpatient setting after undergoing same-day surgery
Time frame: 90 days
emergency room visit
the number of patients who visited the emergency room without subsequent hospitalization after undergoing same-day surgery
Time frame: 90 days
re-hospitalization
the number of patients who have to be readmitted to the hospital after being discharged home following their same-day surgery
Time frame: 90 days
major cardiovascular complications
the number of patients who have at least one of the following: myocardial injury or infarction, non-fatal cardiac arrest, coronary revascularization, stroke, transient ischemic attack, new clinically significant arrythmia, congestive heart failure, unplanned postoperative admission for vascular reasons, emergency room visit for vascular reasons, rehospitalization for vascular reasons, and all-cause mortality
Time frame: 90 days
myocardial injury after noncardiac surgery (MINS)
the number of patients who experience a MINS
Time frame: 90 days
myocardial infarction
the number of patients who experience a myocardial infarction
Time frame: 90 days
non-fatal cardiac arrest
the number of patients who experience a non-fatal cardiac arrest
Time frame: 90 days
coronary revascularization
the number of patients who undergo coronary revascularization
Time frame: 90 days
stroke
the number of patients who experience a stroke
Time frame: 90 days
transient ischemic attack
the number of patients who experience a transient ischemic attack
Time frame: 90 days
new clinically important arrythmia
the number of patients who experience a new clinically important arrythmia
Time frame: 90 days
acute congestive heart failure
the number of patients who experience an acute congestive heart failure episode
Time frame: 90 days
deep vein thrombosis
the number of patients who experience a deep vein thrombosis
Time frame: 90 days
pulmonary embolism
the number of patients who experience a pulmonary embolism
Time frame: 90 days
major postoperative and life-threatening bleeding
the number of patients who experience a major postoperative and/or life-threatening bleeding
Time frame: 90 days
postoperative infection
the number of patients who experience a postoperative infection
Time frame: 90 days
acute kidney injury
the number of patients who experience a acute kidney injury
Time frame: 90 days
quality of life score on the 5-level EQ-5D version (EQ-5D-5L) questionnaire
score on the EQ-5D-5L questionnaire on 4 health profiles (level 1 to 5), overall self-rated health status (0-100 visual analogue scale), and EQ-5D-5L index value (0.01-0.99)
Time frame: 90 days
functional capacity score on the Duke Activity Status Index (DASI)
change in the score on the Duke Activity Status Index (DASI) questionnaire (0 to 58.2 points)
Time frame: 90 days
frailty
change in the level on the Clinical Frailty Scale (level 1 to 9)
Time frame: 90 days
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 61 months after the start.
Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's planned 61 months is above that.
Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre hospitalier de l'Université de Montréal (CHUM) →